Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TGX 007

Next Previous
Drug Profile

TGX 007

Alternative Names: TGX-007

Latest Information Update: 04 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Trogenix
  • Class Antineoplastics; Gene-directed enzyme-prodrug therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Immunologic cytotoxicity; Interleukin 12 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glioblastoma

Most Recent Events

  • 27 Jan 2026 Preclinical trials in Glioblastoma in United Kingdom (Intratumoural) prior to January 2026
  • 27 Jan 2026 Pharmacodynamics data from a preclinical studies in Glioblastoma released by Trogenix (Trogenix website, January 2026)
  • 16 Jan 2026 Trogenix plans a phase I/II ADePT trial for Glioblastoma (First line-therapy, Second line therapy or greater) in United Kingdom and USA (Intratumoral, Injection) (NCT07346144)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top